Annex Advisory Services LLC Sells 5,431 Shares of Johnson & Johnson $JNJ

Key Points

• Annex Advisory Services reduced its Johnson & Johnson stake by 16%, selling 5,431 shares and retaining 28,619 shares valued at approximately $7.27 million. Institutional investors collectively own 69.55% of J&J.
• J&J reported better-than-expected second-quarter results, with revenue up 6.6% year over year to $25.31 billion and adjusted EPS of $2.90. The FDA’s authorization of its OTTAVA robotic surgery system also adds a potential long-term MedTech growth opportunity.
• Analysts maintain a generally positive outlook, with a consensus “Moderate Buy” rating and an average price target of $268.22, although shares trade at roughly 30 times earnings and face patent, litigation and competitive risks. The company declared a quarterly dividend of $1.34 per share, representing a 2.1% yield.

Annex Advisory Services LLC cut its holdings in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 16.0% during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 28,619 shares of the company's stock after selling 5,431 shares during the quarter. Annex Advisory Services LLC's holdings in Johnson & Johnson were worth $7,268,000 at the end of the most recent quarter.

A number of other institutional investors also recently made changes to their positions in the business. Blueline Advisors LLC purchased a new position in Johnson & Johnson in the 4th quarter worth $25,000. Cresta Advisors Ltd. purchased a new stake in Johnson & Johnson during the fourth quarter valued at about $26,000. DecisionPoint Financial LLC grew its stake in shares of Johnson & Johnson by 104.2% during the fourth quarter. DecisionPoint Financial LLC now owns 147 shares of the company's stock valued at $30,000 after buying an additional 75 shares during the last quarter. Bay Harbor Wealth Management LLC grew its stake in shares of Johnson & Johnson by 49.0% during the fourth quarter. Bay Harbor Wealth Management LLC now owns 149 shares of the company's stock valued at $31,000 after buying an additional 49 shares during the last quarter. Finally, Family CFO Inc purchased a new position in shares of Johnson & Johnson in the fourth quarter worth about $31,000. Hedge funds and other institutional investors own 69.55% of the company's stock.

Johnson & Johnson News Summary

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Johnson & Johnson’s fiscal second-quarter results exceeded expectations, with revenue rising 6.6% year over year to $25.31 billion and adjusted earnings per share reaching $2.90. The company also raised or reaffirmed its full-year outlook, reinforcing confidence in operating momentum. Johnson & Johnson vs. Medtronic
• Positive Sentiment: The FDA granted De Novo authorization for J&J’s OTTAVA soft-tissue robotic surgery system, giving its MedTech business an entry point into a growing market and potentially creating a new source of long-term growth. OTTAVA FDA approval
• Positive Sentiment: Additional growth initiatives include a preferred cardiac electrophysiology technology agreement with ACCESS for ambulatory surgery centers, a priority review for RYBREVANT FASPRO, and a collaboration focused on in vivo CAR-T therapies. ACCESS strategic agreement
• Neutral Sentiment: Analysts and commentators generally view JNJ as a hold or moderate buy. Shares are trading above their 50-day and 200-day moving averages, but the stock’s strong rally leaves less valuation support; investors are weighing its roughly 30 times earnings multiple against future growth. JNJ nearing its 52-week high
• Negative Sentiment: Patent expirations, MedTech competition, pipeline execution risks and ongoing talc litigation remain important overhangs. J&J’s proposed $5.5 billion talc settlement framework could reduce legal uncertainty, but it also highlights the potential for substantial cash costs and continued investor scrutiny. OTTAVA FDA win and talc deal

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on JNJ shares. Johnson Rice reissued a "buy" rating on shares of Johnson & Johnson in a research note on Monday, August 3rd. Barclays lifted their price target on Johnson & Johnson from $234.00 to $255.00 and gave the stock an "equal weight" rating in a research note on Wednesday, April 15th. Freedom Capital upgraded Johnson & Johnson from a "hold" rating to a "strong-buy" rating in a research report on Thursday, July 16th. Weiss Ratings raised Johnson & Johnson from a "buy (b-)" rating to a "buy (b)" rating in a research note on Friday, July 24th. Finally, Argus set a $300.00 target price on shares of Johnson & Johnson in a report on Wednesday, July 29th. One research analyst has rated the stock with a Strong Buy rating, eighteen have given a Buy rating and six have given a Hold rating to the company's stock. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average price target of $268.22.

Johnson & Johnson Stock Down 1.0%

Shares of NYSE JNJ opened at $259.28 on Wednesday. The firm has a fifty day simple moving average of $249.94 and a two-hundred day simple moving average of $240.47. Johnson & Johnson has a 12 month low of $171.81 and a 12 month high of $274.90. The company has a current ratio of 1.09, a quick ratio of 0.81 and a debt-to-equity ratio of 0.44. The firm has a market capitalization of $624.84 billion, a PE ratio of 30.04, a price-to-earnings-growth ratio of 2.50 and a beta of 0.24.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its earnings results on Wednesday, July 15th. The company reported $2.90 earnings per share for the quarter, beating analysts' consensus estimates of $2.84 by $0.06. Johnson & Johnson had a net margin of 21.48% and a return on equity of 32.42%. The firm had revenue of $25.31 billion for the quarter, compared to analyst estimates of $25.06 billion. During the same quarter in the previous year, the firm posted $2.77 EPS. The company's revenue for the quarter was up 6.6% compared to the same quarter last year. Johnson & Johnson has set its FY 2026 guidance at 11.600-11.750 EPS. Equities analysts expect that Johnson & Johnson will post 11.61 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 8th. Shareholders of record on Tuesday, August 25th will be given a dividend of $1.34 per share. This represents a $5.36 annualized dividend and a yield of 2.1%. The ex-dividend date of this dividend is Tuesday, August 25th. Johnson & Johnson's payout ratio is presently 62.11%.

Insiders Place Their Bets

In other news, EVP Vanessa Broadhurst sold 23,054 shares of the stock in a transaction that occurred on Monday, July 20th. The stock was sold at an average price of $251.27, for a total value of $5,792,778.58. Following the completion of the transaction, the executive vice president owned 23,003 shares of the company's stock, valued at approximately $5,779,963.81. This represents a 50.06% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Kathryn E. Wengel sold 10,000 shares of the firm's stock in a transaction that occurred on Thursday, June 11th. The shares were sold at an average price of $241.15, for a total value of $2,411,500.00. Following the completion of the transaction, the executive vice president owned 114,288 shares of the company's stock, valued at approximately $27,560,551.20. The trade was a 8.05% decrease in their position. The SEC filing for this sale provides additional information. In the last quarter, insiders have sold 48,972 shares of company stock worth $12,295,205. Company insiders own 0.16% of the company's stock.

About Johnson & Johnson

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company's pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source